房颤消融与药物治疗疗效的性别差异:CABANA 试验结果
CABANA 试验随机纳入 2204 例房颤患者,比较导管消融与药物治疗策略。女性占 37%,两组主要复合终点风险比在女性为 1.01(95%CI 0.62-1.65)、男性为 0.73(95%CI 0.51-1.05),交互 P=0.299;房颤复发风险消融均优于药物,但男性获益更大(交互 P=0.060)。结论支持消融对男女均有效。
要点
- 女性房颤患者消融与药物主要终点无显著差异,男性消融有获益趋势但交互检验无统计学意义。
- 消融降低房颤复发风险男女均显著,男性降幅更大(HR 0.48 vs 女性 0.64)。
- 两性治疗相关并发症均少见,未见性别差异。
核心结论
- CABANA 试验未发现男女在消融与药物策略的主要和次要临床结局上存在临床相关差异,不良事件无性别差异。
- 消融对男女房颤患者均是有效治疗策略。
研究设计与样本
- CABANA 为随机对照试验,纳入 2204 例房颤患者,随机接受导管消融(肺静脉隔离)或药物(率/律控制)治疗。
- 女性 819 例(37%,消融 413 例、药物 406 例),男性 1385 例(消融 695 例、药物 690 例)。
- 入组标准:年龄≥65 岁,或<65 岁且至少 1 项卒中危险因素。
- 主要复合终点为死亡、致残性卒中、严重出血或心脏骤停;关键次要终点包括房颤复发。
主要发现
- 女性较男性年龄更大(中位 69 岁 vs 67 岁)、症状更重(加拿大心血管学会房颤严重分级 3/4 级 48% vs 39%)、症状性心衰更多(NYHA≥II 级 42% vs 32%)、阵发性房颤更多(50% vs 39%),P 均<0.0001。
- 女性接受非肺静脉消融的比例低于男性(55.7% vs 62.2%,P=0.043)。
- 主要终点消融 vs 药物风险比:女性 1.01(95%CI 0.62-1.65),男性 0.73(95%CI 0.51-1.05),交互 P=0.299。
- 房颤复发风险消融 vs 药物:女性 HR 0.64(95%CI 0.51-0.82),男性 HR 0.48(95%CI 0.40-0.58),交互 P=0.060。
- 两性治疗相关并发症均少见。
临床怎么用
- 房颤患者选择消融或药物策略时,不应因性别而区别对待,消融对男女均有效。
- 女性患者常症状更重、年龄更大,消融决策时应综合评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Among patients with atrial fibrillation (AF), women are less likely to receive catheter ablation and may have more complications and less durable results. Most information about sex-specific differences after ablation comes from observational data. We prespecified an examination of outcomes by sex in the 2204-patient CABANA trial (Catheter Ablation Versus Antiarrhythmic Drug Therapy for Atrial Fibrillation). METHODS: CABANA randomized patients with AF age ≥65 years or <65 years with ≥1 risk factor for stroke to a strategy of catheter ablation with pulmonary vein isolation versus drug therapy with rate/rhythm control agents. The primary composite outcome was death, disabling stroke, serious bleeding, or cardiac arrest, and key secondary outcomes included AF recurrence. RESULTS: CABANA randomized 819 (37%) women (ablation 413, drug 406) and 1385 men (ablation 695, drug 690). Compared with men, women were older (median age, 69 years versus 67 years for men), were more symptomatic (48% Canadian Cardiovascular Society AF Severity Class 3 or 4 versus 39% for men), had more symptomatic heart failure (42% with New York Heart Association Class ≥II versus 32% for men), and more often had a paroxysmal AF pattern at enrollment (50% versus 39% for men) (P<0.0001 for all). Women were less likely to have ancillary (nonpulmonary vein) ablation procedures performed during the index procedure (55.7% versus 62.2% in men, P=0.043), and complications from treatment were infrequent in both sexes. For the primary outcome, the hazard ratio for those who underwent ablation versus drug therapy was 1.01 (95% CI, 0.62-1.65) in women and 0.73 (95% CI, 0.51-1.05) in men (interaction P value=0.299). The risk of recurrent AF was significantly reduced in patients undergoing ablation compared with those receiving drug therapy regardless of sex, but the effect was greater in men (hazard ratio, 0.64 [95% CI, 0.51-0.82] for women versus hazard ratio, 0.48 [95% CI, 0.40-0.58] for men; interaction P value=0.060). CONCLUSIONS: Clinically relevant treatment-related strategy differences in the primary and secondary clinical outcomes of CABANA were not seen between men and women, and there were no sex differences in adverse events. The CABANA trial results support catheter ablation as an effective treatment strategy for both women and men. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT00911508.
引用
- Russo AM, Zeitler EP, Giczewska A, et al. Association Between Sex and Treatment Outcomes of Atrial Fibrillation Ablation Versus Drug Therapy: Results From the CABANA Trial. Circulation. 2021. PMID: 33499668. doi:10.1161/CIRCULATIONAHA.120.051558
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。